Cord blood lipids in infants born to HIV-1-infected women treated with combination antiretroviral therapy

Antiviral Therapy

Volumn 13, Issue 3, 2008, Pages 349-355

  Melvin, Ann J ^a   Kang, Minhee ^b   Hitt, Jane ^a   Livingston, Elizabeth ^c   Cohn, Susan E ^d   Stocker, Vicki ^e   Ross, Allison C ^f   Watts, Heather ^g   McComsey, Grace A ^f  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b CENTER FOR BIOSTATISTICS IN AIDS RESEARCH   (United States)

^c DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^e AIDS Clinical Trials Group Operations Center   (United States)

^f CASE WESTERN RESERVE UNIVERSITY   (United States)

^g EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; APOLIPOPROTEIN A1; APOLIPOPROTEIN B100; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INDINAVIR; LIPOPROTEIN; LOPINAVIR PLUS RITONAVIR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NELFINAVIR; PROTEINASE INHIBITOR; SAQUINAVIR; TRIACYLGLYCEROL; ZIDOVUDINE; ANTIRETROVIRUS AGENT; APOA1 PROTEIN, HUMAN; APOLIPOPROTEIN B; LIPOPROTEIN A;

ALCOHOL CONSUMPTION; ARTICLE; BIRTH WEIGHT; BODY MASS; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; CONTROLLED STUDY; COVARIANCE; DELIVERY; ETHNICITY; FEMALE; FETUS OUTCOME; GENDER; GESTATIONAL AGE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HYPOGLYCEMIA; INFANT; LIPOPROTEIN BLOOD LEVEL; MATERNAL SMOKING; MATERNAL TREATMENT; MONOTHERAPY; PRENATAL EXPOSURE; PRIORITY JOURNAL; PUERPERIUM; RACE; SIDE EFFECT; STATISTICAL SIGNIFICANCE; TREATMENT DURATION; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; UMBILICAL CORD BLOOD; BLOOD; CLINICAL TRIAL; DISEASE TRANSMISSION; DRUG COMBINATION; FETUS BLOOD; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; METABOLISM; MULTICENTER STUDY; NEWBORN; PREGNANCY; PREGNANCY COMPLICATION; PROSPECTIVE STUDY; UNITED STATES; VIROLOGY;

ANTI-RETROVIRAL AGENTS; APOLIPOPROTEIN A-I; APOLIPOPROTEINS B; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DRUG THERAPY, COMBINATION; FEMALE; FETAL BLOOD; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; INFANT, NEWBORN; LIPOPROTEIN(A); MALE; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PROSPECTIVE STUDIES; TREATMENT OUTCOME; TRIGLYCERIDES; UNITED STATES;

EID: 47249106951     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. CDC. Achievements in public health: reduction in perinatal transmission of HIV infection - United States, 1985-2005. MMWR 2006; 55:592-597.
2. European Collaborative Study. The mother-to-child HIV transmission epidemic in Europe: evolving in the East and established in the West. AIDS 2006; 20:1419-1427.
3. Blanche S, Tardieu M, Rustin P, et al. Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues. Lancet 1999; 354:1084-1089.
4. Brogly SB, Ylitalo N, Mofenson LM, et al. In utero nucleoside reverse transcriptase inhibitor exposure and signs of possible mitochondrial dysfunction in HIV-uninfected children. AIDS 2007; 21:929-938.
5. Noguerra A, Fortuny C, Munoz-Almagro C, et al. Hyperlactatemia in human immunodeficiency virus-uninfected infants who are exposed to antiretrovirals. Pediatr 2004; 114:e598-e603.
6. Bulterys M, Nesheim S, Abrams EJ, et al. Lack of evidence of mitochondrial dysfunction in the offspring of HIV-infected women. Retrospective review of perinatal exposure to antiretroviral drugs in the Perinatal AIDS Collaborative Transmission Study. Ann NY Acad Sci 2000; 918:212-221.
7. The Perinatal Safety Review Working Group. Nucleoside exposure in the children of HIV-infected women receiving antiretroviral drugs: absence of clear evidence for mitochondrial disease in children who died before 5 years of age in five United States cohorts. J Acquir Immune Defic Syndr 2000; 25:261-268.
8. Melvin AJ, Lennon S, Mohan K, Purnell JQ. Metabolic abnormalities in HIV type 1-infected children treated and not treated with protease inhibitors. AIDS Res Hum Retro 2001; 17:1117-1123.
9. Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999; 353:2093-2099.
10. Periard D, Telenti A, Sudre P, et al. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study. Circulation 1999; 100:700-705.
11. Kulasegaram R, Peters BS, Wierzbicki AS. Dyslipidaemia and cardiovascular risk in HIV infection. Curr Med Res Opin 2005; 21:1717-1725.
12. Perinatal HIV Guidelines Working Group. Public Health Service task force recommendations for use of antiretroviral drugs in pregnant HIV-1 infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States. (Updated 12 October 2006. Accessed 13 July 2007.) Available from http://aidsinfo.nih.gov/ContentFiles/PerinatalGL.pdf
13. Napoli C, Glass CK, Witztum JL, Deutsch R, D'Armiento FP, Palinski W. Influence of maternal hypercholesterolaemia during pregnancy on progression of early atherosclerotic lesions in childhood: Fate of Early Lesions in Children (FELIC) study. Lancet 1999; 354:1234-1241.
14. Fonnebo V, Dahl LB, Moe PJ, Ingebretsen OC. Does VLDL-LDL-cholesterol in cord serum predict future level of lipoproteins? Acta Paediatr Scand 1991; 80:780-785.
15. Barker DJ, Martyn CN, Osmond C, Hales CN, Fall CH. Growth in utero and serum cholesterol concentrations in adult life. BMJ 1993; 307:1524-1527.
16. Kallio MJ, Salmenpera L, Siimes MA, Perheentupa J, Miettinen TA. Tracking of serum cholesterol and lipoprotein levels from the first year of life. Pediatr 1993; 91:949-954.
17. Bastida S, Sanchez-Muniz FJ, Cuena R, Perea S, Aragones A. High density lipoprotein-cholesterol changes in children and high cholesterol levels at birth. Eur J Pediatr 2002; 161:94-98.
18. Rodie VA, Caslake MJ, Stewart F, et al. Fetal cord plasma lipoprotein status in uncomplicated human pregnancies and in pregnancies complicated by pre-eclampsia and intrauterine growth restriction. Atherosclerosis 2004; 176:181-187.
19. Bansal N, Cruickshank JK, McElduff P, Durrington PN. Cord blood lipoproteins and prenatal influences. Curr Opin Lipidol 2005; 16:400-408.
20. Hitti J, Andersen J, McComsey G, et al. Protease inhibitor-based antiretroviral therapy and glucose tolerance in pregnancy: AIDS Clinical Trials Group A5084. Am J Obstet Gynecol 2007; 196:331.e1-331.e7.
21. Livingston EG, Cohn SE, Yang Y, et al. Lipids and lactate in human immunodeficiency virus-1-infected pregnancies with or without protease inhibitor-based therapy. Obstet Gynecol 2007; 110:391-397.
22. Working Group on Antiretroviral Therapy and Medical Management of HIV-infected Children. Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection. (Updated 26 October 2006. Accessed 13 July 2007.) Available from http://aidsinfo.nih.gov/ContentFiles/PediatricGuidelines.pdf
23. Division of AIDS table for grading the severity of adult and pediatric adverse events. (Updated 23 December 2004. Accessed 7 April 2008.) Available from http://rcc.tech-res.com/tox_tables.htm.
24. Cotter AM, Garcia AG, Duthely ML, Luke B, O'Sullivan M. Is antiretroviral therapy during pregnancy associated with an increased risk of preterm delivery, low birth weight, or stillbirth? J Infect Dis 2006; 193:1195- 1201.
25. Tuomala RE, Shapiro DE, Mofenson LM, et al. Antiretroviral therapy during pregnancy and the risk of an adverse outcome. N Engl J Med 2002; 346:1863-1870.
26. Bastida S, Cuesta C, Perea S, Aragones A, Sanchez-Muniz FJ. Lipid and lipoprotein changes throughout the term-period in neonates from the Toledo Study. J Physiol Biochem 1996; 52:23-30.
27. Loughrey CM, Rimm E, Heiss G, Rifai N. Race and gender differences in cord blood lipoproteins. Atherosclerosis 2000; 148:57-65.
28. Kwiterovich PO, Virgil DG, Garrett ES, et al. Lipoprotein heterogeneity at birth: influences of gestational age and race on lipoprotein subclasses and Lp(a) lipoprotein. Ethn Dis 2004; 14:351-359.
29. Diaz M, Leal C, Ramon y Cajal J, et al. Cord blood lipoprotein-cholesterol: relationship birth weight and gestational age of newborns. Metabolism 1989; 38:435-438.
30. Bastida S, Sanchez-Muniz FJ, Cuesta C, Perea S, Aragones A. Male and female cord blood lipoprotein profile differences throughout the term-period. J Perinat Med 1997; 25:184-191.
31. Marzolini C, Rudin C, Decosterd L, et al. Transplacental passage of protease inhibitors at delivery. AIDS 2002; 16:889-893.
32. Gingelmaier A, Kurowski M, Kastner M, et al. Placental transfer and pharmacokinetics of lopinavir and other protease inhibitors in combination with nevirapine at delivery. AIDS 2006; 20:1737-1743.
33. Glueck CJ, Heckman F, Schoenfeld M, Steiner P, Pearce W. Neonatal familial type II hyperlipidemia: cord blood cholesterol in 1800 births. Metabolism 1971; 20:597-608.
34. Sanchez-Muniz FJ, Bastida S, Perea S, Cuesta C, Aragones A. Low density lipoprotein in neonates with high cord serum cholesterol levels. Acta Pediatr 1997; 86:414-418.
35. Goldstein JL, Albers JJ, Schrott HG, Hazzard WR, Bierman EL, Motulsky AG. Plasma lipid levels and coronary heart disease in adult relatives of newborns with normal and elevated cord blood lipids. Am J Hum Genet 1974; 26:727-735.
36. Riddler SA, Smit E, Cole SR, et al. Impact of HIV infection and HAART on serum lipids in men. JAMA 2003; 289:2978-2982.